Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.
Schmoll HJ, Mann J, Meinert F, Garlipp B, Borchert K, Vogel A, Goekkurt E, Kaiser U, Hoeffkes HG, Rüssel J, Kanzler S, Edelmann T, Forstbauer H, Göhler T, Hannig C, Hildebrandt B, Roll C, Bokemeyer C, Steighardt J, Cygon F, Ibach S, Stein A, Tintelnot J. Schmoll HJ, et al. Among authors: gohler t. Br J Cancer. 2024 Feb;130(2):233-241. doi: 10.1038/s41416-023-02496-4. Epub 2023 Nov 23. Br J Cancer. 2024. PMID: 37996507 Free PMC article.
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy.
Harbeck N, Kates R, Schinköthe T, Schumacher J, Wuerstlein R, Degenhardt T, Lüftner D, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Fasching PA, Schmidt M; AGO-B, WSG PreCycle investigators. Harbeck N, et al. Among authors: gohler t. Cancer Treat Rev. 2023 Dec;121:102631. doi: 10.1016/j.ctrv.2023.102631. Epub 2023 Oct 18. Cancer Treat Rev. 2023. PMID: 37862832 Review.
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Kröning H, Göhler T, Decker T, Grundeis M, Kojouharoff G, Lipke J, Semsek D, Moorahrend E, Sauer A, Bruch HR, Liersch R, Nusch A, Vehling-Kaiser U, Welslau M, Grunewald R, Harich HD, Stephany M, Uhlig J, de Buhr R, Frank M, Hogrefe C, Marschner N, Potthoff K, Hartmann F, Reisländer T, Schwaner I. Kröning H, et al. Among authors: gohler t. Int J Cancer. 2023 Sep 15;153(6):1227-1240. doi: 10.1002/ijc.34603. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260368
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators (see Appendix 1). Harbeck N, et al. Among authors: gohler t. Ann Oncol. 2023 Aug;34(8):660-669. doi: 10.1016/j.annonc.2023.05.003. Epub 2023 May 16. Ann Oncol. 2023. PMID: 37201751 Free article. Clinical Trial.
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.
Reinisch M, Untch M, Mahlberg R, Reimer T, Hitschold T, Marmé F, Aydogdu M, Schmatloch S, Lück HJ, Schmidt M, Ladda E, Sinn BV, Klare P, Janni W, Jackisch C, Denkert C, Seiler S, Göhler T, Michel L, Burchardi N, Stickeler E, Rey J, Klutinus N, Möbus V, Loibl S. Reinisch M, et al. Among authors: gohler t. Breast. 2022 Dec;66:110-117. doi: 10.1016/j.breast.2022.10.002. Epub 2022 Oct 5. Breast. 2022. PMID: 36223695 Free PMC article. Clinical Trial.
A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer.
Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D, Weniger S, Belka C, Bergmann T, Göhler T, Welslau M, Große-Thie C, Guntinas-Lichius O, von der Grün J, Balermpas P, Orlowski K, Messinger D, Stenzel KG, Fietkau R. Hecht M, et al. Among authors: gohler t. Cancers (Basel). 2021 Jul 8;13(14):3413. doi: 10.3390/cancers13143413. Cancers (Basel). 2021. PMID: 34298628 Free PMC article.
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer.
Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D, Weniger S, Belka C, Bergmann T, Göhler T, Welslau M, Große-Thie C, Guntinas-Lichius O, von der Grün J, Balermpas P, Orlowski K, Messinger D, Stenzel KG, Fietkau R. Hecht M, et al. Among authors: gohler t. BMC Cancer. 2020 Sep 29;20(1):933. doi: 10.1186/s12885-020-07440-w. BMC Cancer. 2020. PMID: 32993574 Free PMC article. Clinical Trial.
30 results